See more : Livechain Inc. (LICH) Income Statement Analysis – Financial Results
Complete financial analysis of Meiji Holdings Co., Ltd. (2269.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Meiji Holdings Co., Ltd., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- Sparinvest – Value Virksomhedsobligationer Global Højrente Udb. KL (SPIVHYKLA.CO) Income Statement Analysis – Financial Results
- Klaria Pharma Holding AB (publ.) (KLAR.ST) Income Statement Analysis – Financial Results
- SATYAM SILK MILLS LTD. (ZSATYASL.BO) Income Statement Analysis – Financial Results
- Tele2 AB (publ) (TLTZF) Income Statement Analysis – Financial Results
- The PNC Financial Services Group, Inc. (PNC) Income Statement Analysis – Financial Results
Meiji Holdings Co., Ltd. (2269.T)
About Meiji Holdings Co., Ltd.
Meiji Holdings Co., Ltd., through its subsidiaries, manufactures and sells dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, drinking milk, beverages, cheese, butter and margarine, cream, ice cream, frozen foods, chocolates, gummy products, chewing gums, candies, sports nutrition products, infant and eternal formula, beauty supplements, OTC drugs, livestock products, and sugar, as well as transportation and distribution services. The company also provides drugs for infectious diseases and central nervous system disorders, as well as generic drugs; agricultural and livestock chemicals; human and veterinary vaccines, and blood plasma products; and veterinary drugs for livestock and fisheries comprising antimicrobial injection, oral administration, antipyretic, analgesic, anti-inflammatory, hemostatic, and breeding agents, disinfectants, insecticides, anthelmintics, metabolites, feed additives, and mixed feed; and companion animals, including anesthetics and painkillers, anti-parasitic and gastrointestinal drugs, anti-bacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,105.49B | 1,062.16B | 1,013.09B | 1,191.77B | 1,252.71B | 1,254.38B | 1,240.86B | 1,242.48B | 1,223.75B | 1,161.15B | 1,148.08B | 1,126.52B | 1,109.28B | 1,114.10B | 1,106.66B | 711.39B | 706.99B | 702.75B | 710.91B |
| Cost of Revenue | 768.61B | 755.35B | 689.84B | 742.14B | 790.18B | 797.81B | 785.98B | 781.15B | 778.18B | 757.77B | 754.01B | 743.84B | 738.50B | 732.86B | 734.68B | 522.66B | 516.33B | 502.64B | 515.71B |
| Gross Profit | 336.88B | 306.80B | 323.25B | 449.63B | 462.52B | 456.57B | 454.88B | 461.33B | 445.56B | 403.39B | 394.06B | 382.69B | 370.78B | 381.24B | 371.98B | 188.74B | 190.66B | 200.12B | 195.20B |
| Gross Profit Ratio | 30.47% | 28.88% | 31.91% | 37.73% | 36.92% | 36.40% | 36.66% | 37.13% | 36.41% | 34.74% | 34.32% | 33.97% | 33.42% | 34.22% | 33.61% | 26.53% | 26.97% | 28.48% | 27.46% |
| Research & Development | 34.88B | 30.99B | 33.44B | 31.40B | 31.45B | 29.18B | 26.51B | 26.16B | 27.31B | 26.11B | 26.07B | 26.20B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 176.69B | 172.00B | 168.44B | 197.12B | 207.08B | 206.31B | 174.96B | 179.19B | 173.23B | 195.66B | 194.23B | 190.41B | 0.00 | 0.00 | 0.00 | 174.70B | 174.40B | 176.52B | 175.21B |
| Selling & Marketing | 40.99B | 39.03B | 39.13B | 144.55B | 150.83B | 149.43B | 156.80B | 165.52B | 165.35B | 154.38B | 160.61B | 161.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 217.68B | 211.03B | 207.56B | 341.68B | 357.91B | 355.74B | 331.76B | 344.71B | 338.58B | 350.04B | 354.84B | 351.56B | 0.00 | 0.00 | 0.00 | 174.70B | 174.40B | 176.52B | 175.21B |
| Other Expenses | 0.00 | -1.27B | -1.99B | 847.00M | -123.00M | 1.44B | 330.00M | 728.00M | 2.11B | 1.24B | 1.53B | 2.68B | 3.55B | 4.67B | 2.73B | 25.00M | 1.00M | 1.00M | 2.00M |
| Operating Expenses | 252.56B | 231.37B | 230.33B | 343.56B | 359.81B | 358.19B | 360.21B | 372.93B | 367.78B | 351.84B | 357.57B | 356.83B | 350.58B | 352.36B | 343.19B | 174.70B | 174.40B | 176.52B | 175.21B |
| Cost & Expenses | 1,021.17B | 986.72B | 920.17B | 1,085.70B | 1,150.00B | 1,156.00B | 1,146.19B | 1,154.08B | 1,145.96B | 1,109.61B | 1,111.58B | 1,100.66B | 1,089.08B | 1,085.22B | 1,077.87B | 697.36B | 690.73B | 679.15B | 690.92B |
| Interest Income | 488.00M | 390.00M | 261.00M | 290.00M | 229.00M | 130.00M | 142.00M | 131.00M | 153.00M | 96.00M | 66.00M | 46.00M | 54.00M | 45.00M | 63.00M | 481.00M | 480.00M | 557.00M | 639.00M |
| Interest Expense | 367.00M | 462.00M | 500.00M | 622.00M | 717.00M | 778.00M | 755.00M | 795.00M | 983.00M | 1.12B | 1.29B | 1.55B | 1.98B | 2.21B | 2.57B | 1.18B | 864.00M | 989.00M | 1.06B |
| Depreciation & Amortization | 55.33B | 53.59B | 50.12B | 48.43B | 46.23B | 44.67B | 48.15B | 47.48B | 43.85B | 42.52B | 41.11B | 40.95B | 41.12B | 41.68B | 39.49B | 20.23B | 22.08B | 19.68B | 20.30B |
| EBITDA | 139.65B | 129.03B | 143.04B | 154.49B | 144.70B | 143.06B | 142.83B | 135.87B | 121.64B | 94.06B | 77.61B | 67.71B | 57.69B | 61.82B | 66.16B | 34.87B | 38.76B | 43.95B | 40.49B |
| EBITDA Ratio | 12.63% | 12.07% | 14.27% | 13.36% | 11.90% | 11.57% | 11.67% | 11.04% | 10.38% | 8.44% | 7.10% | 6.36% | 5.86% | 6.67% | 6.36% | 4.90% | 5.51% | 6.25% | 5.76% |
| Operating Income | 84.32B | 75.43B | 92.92B | 106.06B | 102.71B | 98.38B | 94.67B | 88.40B | 77.78B | 51.54B | 36.50B | 25.86B | 20.19B | 28.87B | 28.79B | 14.04B | 16.26B | 23.60B | 19.99B |
| Operating Income Ratio | 7.63% | 7.10% | 9.17% | 8.90% | 8.20% | 7.84% | 7.63% | 7.11% | 6.36% | 4.44% | 3.18% | 2.30% | 1.82% | 2.59% | 2.60% | 1.97% | 2.30% | 3.36% | 2.81% |
| Total Other Income/Expenses | 3.19B | 19.98B | 35.53B | -2.88B | -4.96B | -3.80B | -3.59B | 797.00M | 17.43B | -2.89B | -2.81B | -645.00M | -5.60B | -12.04B | -4.69B | -2.23B | -446.00M | -2.17B | -856.00M |
| Income Before Tax | 87.51B | 95.41B | 128.46B | 103.18B | 97.75B | 94.59B | 91.08B | 89.19B | 95.21B | 48.66B | 33.69B | 25.21B | 14.59B | 17.93B | 24.10B | 11.81B | 15.82B | 21.43B | 19.13B |
| Income Before Tax Ratio | 7.92% | 8.98% | 12.68% | 8.66% | 7.80% | 7.54% | 7.34% | 7.18% | 7.78% | 4.19% | 2.93% | 2.24% | 1.32% | 1.61% | 2.18% | 1.66% | 2.24% | 3.05% | 2.69% |
| Income Tax Expense | 33.79B | 23.91B | 36.07B | 33.10B | 28.00B | 30.98B | 29.12B | 27.99B | 31.61B | 17.19B | 14.69B | 8.37B | 7.54B | 8.34B | 10.58B | 5.84B | 6.55B | 7.70B | 8.98B |
| Net Income | 50.68B | 69.42B | 87.50B | 65.66B | 67.32B | 61.87B | 61.28B | 60.79B | 62.58B | 30.89B | 19.06B | 16.65B | 6.81B | 9.55B | 13.09B | 5.93B | 9.23B | 13.71B | 10.06B |
| Net Income Ratio | 4.58% | 6.54% | 8.64% | 5.51% | 5.37% | 4.93% | 4.94% | 4.89% | 5.11% | 2.66% | 1.66% | 1.48% | 0.61% | 0.86% | 1.18% | 0.83% | 1.30% | 1.95% | 1.41% |
| EPS | 181.64 | 247.39 | 303.62 | 226.26 | 232.04 | 221.93 | 211.08 | 206.56 | 212.53 | 104.90 | 64.70 | 56.50 | 23.10 | 32.41 | 44.43 | 4.51 | 7.02 | 10.43 | 8.47 |
| EPS Diluted | 181.64 | 247.39 | 303.62 | 226.26 | 232.04 | 221.93 | 211.08 | 206.56 | 212.53 | 104.90 | 64.70 | 56.50 | 23.10 | 32.41 | 44.43 | 4.51 | 7.02 | 10.43 | 8.47 |
| Weighted Avg Shares Out | 278.98M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M |
| Weighted Avg Shares Out (Dil) | 278.98M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M | 278.78M |
Source: https://incomestatements.info
Category: Stock Reports